NCT00621673View on ClinicalTrials.gov

Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A

PHASE4TerminatedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

May 31, 2006

Study Completion Date

October 31, 2006

Conditions

Hemophilia A

Interventions

DRUG

Kogenate (BAY 14-2222)

Antihemophilic factor (recombinant) 20-40 IU/ kg based on body weight of rFVIII, IV, 3 times a week

Trial Locations (2)

48202

Detroit

89109

Las Vegas

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY